Navigation Links
Arena Pharmaceuticals' Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
Date:10/12/2009

A standardized program of moderate diet and exercise guidance is included in the Phase 3 program. The program's hierarchically ordered co-primary efficacy endpoints are: the proportion of patients achieving 5% or greater weight loss after 12 months, the difference in mean weight loss compared to placebo after 12 months, and the proportion of patients achieving 10% or greater weight loss after 12 months. Arena is also studying several key secondary endpoints, including changes in serum lipids, markers of inflammation and insulin resistance, and in the BLOOM-DM trial, other indicators of glycemic control.

About Lorcaserin

Lorcaserin is a novel single agent that represents the first in a new class of selective 5HT-2C receptor agonists. The 5HT-2C receptor is expressed in the brain, including the hypothalamus, an area involved in the control of appetite and metabolism. Stimulation of this receptor is strongly associated with feeding behavior and satiety. Arena has patents that cover lorcaserin in the US and other jurisdictions, which in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena has a broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, which includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals® and Arena® are registered se
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  CytRx Corporation (NASDAQ: CYTR ... oncology, today reported financial results for the three months ... of recent accomplishments and upcoming milestones for its clinical ... has been very productive for CytRx. Enrollment in our ... in soft tissue sarcoma (STS) continues on track to ...
(Date:8/3/2015)... Aug. 3, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... its Second Quarter 2015 Investor Conference Call and webcast ... The call will cover an update on Merrimack,s ... 2015 financials. A press release detailing the information to ... afternoon of Monday, August 10. Investors and the general ...
(Date:8/3/2015)... , Aug. 3, 2015  Celsion Corporation ... Company will host a conference call to discuss ... an update on its development programs for ThermoDox®, ... two newly acquired technology platforms, TheraPlas™ and TheraSilence™, ... EDT on Monday, August 10, 2015. To participate ...
Breaking Medicine Technology:CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2
... BETHLEHEM, Pa., Jan. 3, 2012  Particle Sciences, a leading ... module to its DOSE™ program.  The DOSE™ program ... modeling tools to efficiently arrive at the optimal ... form.  Previously, Particle Sciences implemented software solutions for ...
... Institute ( www.ecri.org ), an independent nonprofit that ... listed 10 health technology issues that hospital leaders ... The just-released list takes into account the convergence ... currently facing healthcare executives. (Photo:  ...
Cached Medicine Technology:Particle Sciences Expands Its DOSE™ Program With Additional Proprietary Modeling Capabilities 2ECRI Institute Puts 10 Technology Issues on its 2012 Watch List for Hospital Executives 2ECRI Institute Puts 10 Technology Issues on its 2012 Watch List for Hospital Executives 3ECRI Institute Puts 10 Technology Issues on its 2012 Watch List for Hospital Executives 4
(Date:8/3/2015)... ... August 03, 2015 , ... Kantor ... in favor of the firm’s client Rebecca Hamsher, deciding that in accordance with ... reimburse benefits for Hamsher’s residential treatment for bulimia, depression and other mental health ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... diseases researchers from the University of Pittsburgh School of Medicine are leading a ... prevention drugs in sub-Saharan Africa. , A cooperative agreement awarded by the ...
(Date:8/3/2015)... Texas (PRWEB) , ... August 03, 2015 , ... ... an agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and precision ... and reduce health care costs. , Annually, more than 8.6 million adverse ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma ... drugs, biologics and consumer health products, today welcomed the announcement by OPKO Health ... Drug Application for a new treatment for chronic kidney disease (CKD) and vitamin ...
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... dental services to help patients in need. Most people know that general health emergencies, ... emergency. Unfortunately, a fewer amount of people know where to turn to during a ...
Breaking Medicine News(10 mins):Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3
... therapy changed as needed, study found , , MONDAY, May ... have only a 50-50 chance that their doctors will ... a new study finds. , Treating high blood pressure ... pressure can lead to increased risk for heart attack, ...
... Medical Center-led pilot study that showed antidepressants can significantly ... cancer patients is the focus of an article published ... the publications produced by the Journal of American Medical ... UNMCs William Lydiatt, M.D., and Bill Burke, M.D., showed ...
... new life as a stroke treatment, researchers say. , ... inhibiting white blood cells and enzymes that, at ... respectively, says Dr. David Hess, chair of the Department ... of Medicine. The broad-spectrum antibiotic also seems to reduce ...
... clinical trial led by a University of North Carolina ... an effective treatment for dysplasia in people with Barretts ... cancer. , The interim results show there is a ... placebo or sham treatment, said Dr. Nicholas Shaheen, principal ...
... International,Meeting, FAIRFAX, Va., May 19 The American ... a cancer,survivor in the Boston area who has dedicated ... the local community. The winner of the Survivor Circle ... on Tuesday, September 23,2008, at the Boston Convention and ...
... NY) Michael Brownlee, M.D., the Anita and Jack ... of Medicine of Yeshiva University, has been selected by ... prestigious David Rumbough Award for Scientific Excellence. The ... to diabetes research. Actress Dina Merrill established this ...
Cached Medicine News:Health News:Many Diabetics Don't Get Necessary Blood Pressure Treatment 2Health News:Many Diabetics Don't Get Necessary Blood Pressure Treatment 3Health News:JAMA publication features study on depression and head and neck cancer 2Health News:Old antibiotic may find new life as a stroke treatment 2Health News:Old antibiotic may find new life as a stroke treatment 3Health News:Radiofrequency ablation is effective treatment for dysplasia in Barrett's esophagus 2Health News:Award Honors Boston Cancer Survivor Who Gives Back 2Health News:Dr. Michael Brownlee receives JDRF Rumbough Award for Scientific Excellence 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: